晚年衰弱与抑郁:一种临床表现独特且抗抑郁反应差的高风险共病
该8周随机安慰剂对照试验随后10个月开放抗抑郁药治疗,纳入121名≥60岁重性抑郁障碍或持续性抑郁障碍且HRSD≥16的成人。潜类别分析识别出持续低衰弱风险(63%)和持续高衰弱风险(37%)两类轨迹;高风险类在12个月内应答和缓解率至少差21个百分点,且后续衰弱与既往衰弱相关而与既往应答或缓解无关。结论认为抗抑郁药对衰弱背景下的老年抑郁效果差,且即使获得应答也难以改善衰弱。
要点
- 老年抑郁合并衰弱者抗抑郁药应答和缓解率显著更差。
- 后续衰弱与既往衰弱相关,与既往抗抑郁应答或缓解无关。
- 建议对抑郁老年人进行常规衰弱评估并探索新治疗策略。
核心结论
- 抗抑郁药对衰弱背景下发生的老年重性抑郁障碍效果差。
- 即使达到抗抑郁应答,对衰弱的改善作用也很小。
- 建议对抑郁老年人的标准精神科评估纳入衰弱测量,并需要针对衰弱与抑郁共病的新治疗策略。
研究设计与样本
- 8周随机安慰剂对照试验(艾司西酞普兰或度洛西汀)随后10个月开放抗抑郁药治疗(增效、换药策略),在门诊研究诊所进行。
- 纳入121名60岁及以上重性抑郁障碍或持续性抑郁障碍且24项汉密尔顿抑郁评定量表(HRSD)≥16的成人。
- 主要指标在12个月内系列评估:应答(HRSD较基线降低50%)、缓解(HRSD<10)和衰弱(非衰弱/中间衰弱[0-2项缺陷] vs 衰弱[≥3项缺陷]);采用潜类别分析分类纵向衰弱轨迹。
主要发现
- 2类模型最佳拟合数据,识别出持续低衰弱风险(样本63%)和持续高衰弱风险(样本37%)轨迹。
- 高风险衰弱类成人12个月内应答和缓解率(ps≤.002)至少比低风险类差21个百分点。
- 后续衰弱与既往衰弱相关(ps≤.01),但与既往应答或缓解无关(ps≥.10)。
关键数值与推荐
- 应答定义为HRSD评分较基线降低50%。
- 缓解定义为HRSD评分<10。
- 衰弱定义为非衰弱/中间衰弱[0-2项缺陷] vs 衰弱[≥3项缺陷]。
- 高风险衰弱类12个月内应答和缓解率至少比低风险类差21个百分点(ps≤.002)。
临床怎么用
- 对抑郁老年人进行标准精神科评估时应纳入衰弱测量。
- 对合并衰弱的老年抑郁患者,应认识到标准抗抑郁药效果可能较差。
- 需探索针对衰弱与抑郁共病的新治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To investigate the longitudinal relationship between physical frailty, the clinical representation of accelerated biological aging, and antidepressant medication response in older adults with depressive illness. METHODS: An 8-week randomized placebo-controlled trial (escitalopram or duloxetine) followed by 10 months of open antidepressant medication treatment (augmentation, switch strategies) was conducted in an outpatient research clinic. 121 adults aged 60 years or older with major depressive disorder (MDD) or persistent depressive disorder and a 24-item Hamilton Rating Scale for Depression (HRSD) ≥16 were enrolled. Primary measures assessed serially over 12 months include response (50% reduction from baseline HRSD score), remission (HRSD score <10), and frailty (non/intermediate frail [0-2 deficits] vs frail [≥3 deficits]); latent class analysis was used to classify longitudinal frailty trajectories. RESULTS: A 2-class model best fit the data, identifying a consistently low frailty risk (63% of the sample) and consistently high frailty risk (37% of the sample) trajectory. Response and remission rates (ps ≤ .002) for adults in the high-risk frailty class were at least 21 percentage points worse than those in the low-risk class over 12 months. Furthermore, subsequent frailty was associated with previous frailty (ps ≤ .01) but not previous response or remission (ps ≥ .10). CONCLUSIONS: Antidepressant medication is poorly effective for MDD occurring in the context of frailty in older adults. Furthermore, even when an antidepressant response is achieved, this response does little to improve their frailty. These data suggest that standard psychiatric assessment of depressed older adults should include frailty measures and that novel therapeutic strategies to address comorbid frailty and depression are needed.
引用
- Brown PJ, Ciarleglio A, Roose SP, et al. Frailty and Depression in Late Life: A High-Risk Comorbidity With Distinctive Clinical Presentation and Poor Antidepressant Response. J Gerontol A Biol Sci Med Sci. 2022. PMID: 34758065. doi:10.1093/gerona/glab338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。